The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Thanendrarajan S et al. Haematologica. 2017 May 26. pii: haematol.2017.168872. doi: 10.3324/haematol.2017.168872. [Epub ahead of print].

Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma.
Mikulasova A et al. Haematologica. 2017 May 26. pii: haematol.2017.163766. doi: 10.3324/haematol.2017.163766. [Epub ahead of print].

Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.
Bolli N et al. Cancer. 2017 May 23. doi: 10.1002/cncr.30777. [Epub ahead of print].

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myelomarelapsing after autologous transplantation.
Merz M et al. Haematologica. 2017 May 11. pii: haematol.2017.168005. doi: 10.3324/haematol.2017.168005. [Epub ahead of print].

CD38 negative relapse in multiple myeloma after daratumumab based chemotherapy.
Minarik J et al. Eur J Haematol. 2017 May 4. doi: 10.1111/ejh.12902. [Epub ahead of print].

BCL6 Overexpression Alters Gene Expression Profile in a Myeloma Cell Line and Is Associated with Decreased DNA Damage Response.
Tahara K et al. Cancer Sci. 2017 May 23. doi: 10.1111/cas.13283. [Epub ahead of print].

Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.
Sedlarikova L et al. Eur J Haematol. 2017 May 25. doi: 10.1111/ejh.12908. [Epub ahead of print].

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase.
An J et al. Nat Commun. 2017 May 22;8:15398. doi: 10.1038/ncomms15398.

Genetic deletion of sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
Delgado-Calle J et al. Leukemia. 2017 May 22. doi: 10.1038/leu.2017.152. [Epub ahead of print].

Differences in the economic valuation and determining factors of informal care over time: the case of blood cancer.
Ortega-Ortega M et al. Gac Sanit. 2017 May 19. pii: S0213-9111(17)30094-8. doi: 10.1016/j.gaceta.2017.02.006. [Epub ahead of print].

Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T cell therapy.
Fernandez-Poma SM et al. Cancer Res. 2017 May 18. pii: canres.0236.2017. doi: 10.1158/0008-5472.CAN-17-0236. [Epub ahead of print].

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.
Simmons JK et al. Mol Cancer Ther. 2017 May 18. pii: molcanther.0171.2017. doi: 10.1158/1535-7163.MCT-17-0171. [Epub ahead of print].

Inhibiting the osteocyte specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
McDonald MM et al. Blood. 2017 May 17. pii: blood-2017-03-773341. doi: 10.1182/blood-2017-03-773341. [Epub ahead of print].

MM-BMSCs induce naïve CD4+ T lymphocytes dysfunction through fibroblast activation protein α.
Wu X et al. Oncotarget. 2017 Apr 30. doi: 10.18632/oncotarget.17538. [Epub ahead of print].

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.
Templin J et al. Oncotarget. 2017 Apr 28. doi: 10.18632/oncotarget.17534. [Epub ahead of print].

Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.
Vo MC et al. Oncotarget. 2017 Apr 29. doi: 10.18632/oncotarget.17517. [Epub ahead of print].

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B et al. Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319052. [Epub ahead of print].

A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
Lu C et al. Br J Haematol. 2017 May 16. doi: 10.1111/bjh.14686. [Epub ahead of print].

15d-PGJ2 as an endoplasmic reticulum stress manipulator in multiple myeloma in vitro and in vivo.
Sperandio M et al. Exp Mol Pathol. 2017 May 12;102(3):434-445. doi: 10.1016/j.yexmp.2017.05.003. [Epub ahead of print].

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Drent E et al. Mol Ther. 2017 May 13. pii: S1525-0016(17)30210-1. doi: 10.1016/j.ymthe.2017.04.024. [Epub ahead of print].

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.
Xu J et al. Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.
Huhn S et al. Bone Marrow Transplant. 2017 May 15. doi: 10.1038/bmt.2017.91. [Epub ahead of print].

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
Schäfer J et al. Cancer Chemother Pharmacol. 2017 May 12. doi: 10.1007/s00280-017-3335-4. [Epub ahead of print].

Beta-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma.
Savvidou I et al. Mol Cancer Ther. 2017 May 12. pii: molcanther.0624.2016. doi: 10.1158/1535-7163.MCT-16-0624. [Epub ahead of print].

Multi-subgroup gene screening using semi-parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma.
Matsui S et al. Biometrics. 2017 May 12. doi: 10.1111/biom.12716. [Epub ahead of print].

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Xiang RF et al. Cell Death Dis. 2017 May 11;8(5):e2776. doi: 10.1038/cddis.2017.188.

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.
Favreau M et al. Leukemia. 2017 May 11. doi: 10.1038/leu.2017.146. [Epub ahead of print].

HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications.
Harada T et al. Leukemia. 2017 May 11. doi: 10.1038/leu.2017.144. [Epub ahead of print].

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.
Manier S et al. Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.

Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition.
Rizq O et al. Clin Cancer Res. 2017 May 10. pii: clincanres.2735.2016. doi: 10.1158/1078-0432.CCR-16-2735. [Epub ahead of print].

Utilizing BMP-2 muteins for treatment of multiple myeloma.
Seher A et al. PLoS One. 2017 May 10;12(5):e0174884. doi: 10.1371/journal.pone.0174884. eCollection 2017.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Sissung TM et al. Cancer Chemother Pharmacol. 2017 May 9. doi: 10.1007/s00280-017-3323-8. [Epub ahead of print].

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival.
Ohguchi H et al. Leukemia. 2017 May 10. doi: 10.1038/leu.2017.141. [Epub ahead of print].

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis, and cancer stem-like cells.
Ray A et al. Leukemia. 2017 May 8. doi: 10.1038/leu.2017.135. [Epub ahead of print].

Griseofulvin Efficiently Induces Apoptosis in In Vitro Treatment of Lymphoma and Multiple Myeloma.
Schmeel LC et al. Anticancer Res. 2017 May;37(5):2289-2295.

Panobinostat induces CD38 upregulation and augments the anti-myeloma efficacy of daratumumab.
García-Guerrero E et al. Blood. 2017 May 5. pii: blood-2017-03-770776. doi: 10.1182/blood-2017-03-770776. [Epub ahead of print].

Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma.
Shvartsur A J Exp Clin Cancer Res. 2017 May 5;36(1):62. doi: 10.1186/s13046-017-0535-z.

Potential roles of miRNAs and their target genes in human multiple myeloma.
Yang Y et al. Eur J Haematol. 2017 May 3. doi: 10.1111/ejh.12901. [Epub ahead of print].

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.
Kassambara A et al. Nucleic Acids Res. 2017 Apr 29. doi: 10.1093/nar/gkx327. [Epub ahead of print].

Ugi Reaction-Derived α-Acyl Aminocarboxamides Bind to Phosphatidylinositol 3-Kinase-Related Kinases, Inhibit HSF1-Dependent Heat Shock Response, and Induce Apoptosis in Multiple Myeloma Cells.
Bach M et al. J Med Chem. 2017 May 25;60(10):4147-4160. doi: 10.1021/acs.jmedchem.6b01613. Epub 2017 May 8.

Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.
Goodyear OC et al. Oncotarget. 2017 May 2;8(18):30383-30394. doi: 10.18632/oncotarget.16628.